There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

These drugs work similarly but differ in dosage and specific indications (uses). Research suggests that tirzepatide is more ...

Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...

Peptide companies' are creating knock-off versions of these drugs that have not been approved by the FDA and contain ...

GLP-1 drugs such as Wegovy and Ozempic (semaglutide) and Zepbound (tirzepatide) may offer benefits that extend beyond aiding ...

Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...

Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a ...

Men, Baby Boomers, and postgraduate degree-holders were among those most likely to say they wouldn’t choose medication over ...

The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...

A trade organization representing compounding pharmacies that make unbranded versions of the weight loss drugs Mounjaro and ...

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...